Sarepta Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $467,172 | $362,931 | $413,464 | $396,781 |
Gross Profit | 375,481 | 309,667 | 362,905 | 352,605 |
EBITDA | 48,730 | 12,030 | 58,310 | 60,836 |
EBIT | 38,924 | -701 | 45,614 | 45,605 |
Net Income | 33,611 | 6,460 | 36,119 | 45,655 |
Net Change In Cash | 467,172 | 362,931 | 413,464 | 396,781 |
Free Cash Flow | -97,962 | -14,225 | -284,520 | -73,696 |
Cash | 197,855 | 383,622 | 427,290 | 428,430 |
Basic Shares | 100,448 | 94,618 | 99,114 | 105,594 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $1,243,336 | $933,013 | $701,887 | $540,099 |
Gross Profit | 1,092,993 | 793,024 | 604,838 | 476,717 |
EBITDA | -439,196 | -582,116 | -306,081 | -453,379 |
EBIT | -498,088 | -636,715 | -355,423 | -493,118 |
Net Income | -535,977 | -703,488 | -418,780 | -554,128 |
Net Change In Cash | 1,243,336 | 933,013 | 701,887 | 540,099 |
Cost of Revenue | 613,810 | 668,068 | ||
Free Cash Flow | -588,338 | -356,170 | -481,662 | 25,264 |
Cash | 428,430 | 966,777 | 2,115,869 | 1,502,648 |
Basic Shares | 92,398 | 87,559 | 81,262 | 77,956 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.34 |
2024-06-30 | $0.07 |
2024-03-31 | $0.37 |
2023-12-31 | $0.47 |
